Cencora, Inc. (NYSE:COR) Stock Position Trimmed by Genesee Capital Advisors LLC

Genesee Capital Advisors LLC trimmed its holdings in Cencora, Inc. (NYSE:COR) by 0.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,140 shares of the company’s stock after selling 48 shares during the quarter. Genesee Capital Advisors LLC’s holdings in Cencora were worth $1,380,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Concord Wealth Partners acquired a new position in shares of Cencora in the 3rd quarter valued at $30,000. Householder Group Estate & Retirement Specialist LLC increased its position in Cencora by 85.2% during the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock worth $33,000 after buying an additional 69 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in Cencora during the third quarter valued at approximately $41,000. Modus Advisors LLC bought a new position in shares of Cencora in the fourth quarter worth about $54,000. Finally, Carolina Wealth Advisors LLC increased its position in Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock worth $60,000 after acquiring an additional 209 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares in the company, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 73,187 shares of company stock worth $17,790,912. 15.80% of the stock is owned by insiders.

Analysts Set New Price Targets

COR has been the subject of several recent research reports. Evercore ISI upped their price target on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Barclays raised their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Mizuho initiated coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, UBS Group boosted their price objective on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $277.00.

Cencora Price Performance

NYSE:COR opened at $255.38 on Wednesday. The stock has a market capitalization of $49.36 billion, a PE ratio of 34.00, a P/E/G ratio of 1.54 and a beta of 0.49. The firm has a fifty day simple moving average of $238.03 and a 200 day simple moving average of $235.30. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $256.81. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date was Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.